Evaluation of Postprandial Glycaemia in a Healthy Population After Intake of Milk and Oat Based Products

Postprandial glycaemia, insulinaemia and GLP-1 will be measured after intake of test meals with equal amount of carbohydrates (adjusted using bread) and equal amount of total water.

Inclusion criteria

• Male or female 20 to 40 years of age
• BMI 20-27 (±0.5) kg/m²
• Agree to maintain consistent dietary habits and physical activity levels for the duration of the study
• Healthy as determined by medical history and information provided by the volunteer
• Willingness to complete questionnaires and follow instructions associated with the study and to complete all visits
• Has given voluntary, written, informed consent to participate in the study

Exclusion criteria

• Elevated fasting blood glucose (at or above 6.1 mmol/L at fasting on visit 2, 3, 4 or 5)
• Elevated fasting insulin (above 25 mIE/L)
• Women who are pregnant or breast feeding
• Any medical condition(s) or medication(s) known to significantly affect glucose metabolism. Significance to be assessed by the SI
• Use of medication, over-the-counter medication, natural health products or dietary supplements/probiotics that may affect glucose metabolism is prohibited during this study. Significance to be assessed by the SI. Participants who are taking allowed prescribed medications must agree to maintain their current method and dosing regimen during the course of the study unless recommended by their physician.
• Known Type I or Type II diabetes, including women who previously have had gestational diabetes.
• Use of antibiotics within 2 weeks of enrollment
• Metabolic diseases and/or chronic gastrointestinal diseases (IBS, Crohns etc.)
• Allergy to ingredients included in investigational product, placebo or standardized meal
• Participants restricted to a vegetarian or vegan diet
• Intolerance to lactose or gluten
• Individuals who are averse to venous catheterization or capillary blood sampling
• Currently active smokers (or using other tobacco products, and e-cigarettes)
• Unstable medical conditions as determined by SI
• Participation in other clinical research trials
• Individuals who are cognitively impaired and/or who are unable to give informed consent
• Acute infection
• Any other condition which in the SI's opinion may adversely affect the individual's ability to complete the study or its measures or which may pose significant risk to the individual